Management of delayed cerebral ischemia after subarachnoid hemorrhage

被引:0
作者
Charles L. Francoeur
Stephan A. Mayer
机构
[1] CHU de Québec-Université Laval,Critical Care Division, Department of Anesthesiology and Critical Care
[2] Mount Sinai,Department of Neurology (Neurocritical Care)
[3] Icahn School of Medicine at Mount Sinai,Institute for Critical Care Medicine
来源
Critical Care | / 20卷
关键词
Delayed cerebral ischemia; Subarachnoid hemorrhage; Vasospasm; Multimodality monitoring;
D O I
暂无
中图分类号
学科分类号
摘要
For patients who survive the initial bleeding event of a ruptured brain aneurysm, delayed cerebral ischemia (DCI) is one of the most important causes of mortality and poor neurological outcome. New insights in the last decade have led to an important paradigm shift in the understanding of DCI pathogenesis. Large-vessel cerebral vasospasm has been challenged as the sole causal mechanism; new hypotheses now focus on the early brain injury, microcirculatory dysfunction, impaired autoregulation, and spreading depolarization. Prevention of DCI primarily relies on nimodipine administration and optimization of blood volume and cardiac performance. Neurological monitoring is essential for early DCI detection and intervention. Serial clinical examination combined with intermittent transcranial Doppler ultrasonography and CT angiography (with or without perfusion) is the most commonly used monitoring paradigm, and usually suffices in good grade patients. By contrast, poor grade patients (WFNS grades 4 and 5) require more advanced monitoring because stupor and coma reduce sensitivity to the effects of ischemia. Greater reliance on CT perfusion imaging, continuous electroencephalography, and invasive brain multimodality monitoring are potential strategies to improve situational awareness as it relates to detecting DCI. Pharmacologically-induced hypertension combined with volume is the established first-line therapy for DCI; a good clinical response with reversal of the presenting deficit occurs in 70 % of patients. Medically refractory DCI, defined as failure to respond adequately to these measures, should trigger step-wise escalation of rescue therapy. Level 1 rescue therapy consists of cardiac output optimization, hemoglobin optimization, and endovascular intervention, including angioplasty and intra-arterial vasodilator infusion. In highly refractory cases, level 2 rescue therapies are also considered, none of which have been validated. This review provides an overview of current state-of-the-art care for DCI management.
引用
收藏
相关论文
共 873 条
[91]  
Steiner T(2010)Bedside use of a dual aortic balloon occlusion for the treatment of cerebral vasospasm Neurocrit Care 13 385-8
[92]  
Al-Shahi Salman R(2009)Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm South Med J 102 150-3
[93]  
Beer R(1999)Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans Stroke 30 1409-16
[94]  
Christensen H(2010)Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature Neurocrit Care 13 101-8
[95]  
Cordonnier C(2010)Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group Stroke 41 2391-5
[96]  
Csiba L(1993)A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study J Neurosurg 78 537-47
[97]  
Forsting M(2006)Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study Stroke. 37 2326-30
[98]  
Harnof S(2003)No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial J Neurosurg. 99 953-9
[99]  
Klijn CJM(2009)Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article J Neurosurg. 111 171-80
[100]  
Krieger D(2012)Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial Lancet 380 44-9